Physician
Interventional Spine and Pain Physicians, PA
Interventional Spine and Pain Physicians, PA was paid $5.54M by Medicaid between Jan 2018 and Dec 2024, across 68 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 27% of everything it billed.
33Billing provider infoINTERVENTIONAL SPINE AND PAIN PHYSICIANS, PA
MAPLE GROVE, MN 55369
MAPLE GROVE, MN 55369
33aNPI1326398561assigned 09/14/2012
33bProvider typePain Medicine (Anesthesiology) Physician
28Total paid$5.54M
24GClaims139,774
24DCodes billed68
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Pain Medicine (Anesthesiology) Physician providers in Minnesota
Rank by total paid#2 of 11
Median peer was paid$245K
This provider vs. median23×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 25,804 | $192K | |
| 2019 | 22,107 | $688K | |
| 2020 | 14,907 | $740K | |
| 2021 | 22,293 | $1.17M | |
| 2022 | 20,105 | $1.00M | |
| 2023 | 20,394 | $975K | |
| 2024incomplete | 14,164 | $777K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 27% | 39,732 | 35,599 | $1.51M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 19% | 19,958 | 17,839 | $1.06M |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | 15% | 5,660 | 5,424 | $805K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 10% | 15,996 | 6,044 | $574K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 9.8% | 13,880 | 12,859 | $543K |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 5.3% | 3,269 | 3,091 | $295K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | 4.5% | 8,177 | 3,640 | $250K |
| 64483 | 2.6% | 1,480 | 1,416 | $143K | |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 2.6% | 1,790 | 1,271 | $142K |
| 64635 | <1% | 224 | 173 | $33K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 763 | 502 | $22K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 167 | 161 | $21K |
56 more codes
| 64636 | <1% | 362 | $19K | |
| 64493 | <1% | 268 | $18K | |
| G0396 | Alcohol and/or substance (other than tobacco) misuse structured assessment (e.g., audit, dast), and brief intervention 15 to 30 minutes | <1% | 958 | $14K |
| 97161 | <1% | 188 | $13K | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 3,280 | $13K |
| 62321 | <1% | 92 | $9K | |
| 97165 | <1% | 123 | $9K | |
| 64494 | <1% | 185 | $7K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 100 | $6K |
| G0444 | Annual depression screening, 5 to 15 minutes | <1% | 668 | $6K |
| J2704 | Injection, propofol, 10 mg | <1% | 4,917 | $4K |
| 27096 | <1% | 38 | $4K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 2,974 | $3K |
| 20610 | <1% | 118 | $3K | |
| 96127 | <1% | 1,067 | $3K | |
| 81025 | <1% | 485 | $2K | |
| G0442 | Annual alcohol misuse screening, 5 to 15 minutes | <1% | 625 | $2K |
| 64495 | <1% | 61 | $2K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 13 | $1K |
| 99443 | <1% | 32 | $1K | |
| 99442 | <1% | 59 | $1K | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 534 | $649.77 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 2,889 | $431.17 |
| 99408 | <1% | 116 | $287.79 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 827 | $283.81 |
| 83992 | <1% | 188 | $249.03 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 432 | $247.91 |
| 77002 | <1% | 12 | $170.33 | |
| 80346 | <1% | 160 | $109.68 | |
| 80372 | <1% | 225 | $109.68 | |
| 80373 | <1% | 204 | $109.68 | |
| 80375 | <1% | 169 | $109.68 | |
| 80351 | <1% | 167 | $109.68 | |
| 80364 | <1% | 220 | $109.68 | |
| 80354 | <1% | 225 | $109.68 | |
| 80365 | <1% | 225 | $109.68 | |
| 80356 | <1% | 188 | $109.68 | |
| 80348 | <1% | 225 | $109.68 | |
| 80353 | <1% | 188 | $109.68 | |
| 80371 | <1% | 188 | $109.68 | |
| 80357 | <1% | 188 | $109.68 | |
| 80324 | <1% | 188 | $109.68 | |
| 80349 | <1% | 173 | $109.68 | |
| 80358 | <1% | 225 | $109.68 | |
| 99484 | <1% | 62 | $94.26 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 2,139 | $88.59 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 954 | $54.11 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 34 | $0.31 |
| 80321 | 0% | 100 | $0.00 | |
| 80369 | 0% | 49 | $0.00 | |
| 80339 | 0% | 91 | $0.00 | |
| 80360 | 0% | 73 | $0.00 | |
| 80355 | 0% | 77 | $0.00 | |
| 80366 | 0% | 77 | $0.00 | |
| 80359 | 0% | 176 | $0.00 | |
| 80368 | 0% | 77 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialWOLFF, JASON (PARTNER)
| Provider | Location | Paid |
|---|---|---|
| Metropolitan Surgical Center, LLC | Maple Grove, MN | $1.29M |
| Pain Centers of Minnesota - Chaska, LLC | Chaska, MN | $1K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.